This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Dominik Maurer
Vice President & Global head of Immunology at Immatics Biotechnologies GmbH


For 10+ years Dominik has been active in the field of cancer immunotherapy and a leader in human T-cell biology. He invented and developed with his team the Immatics’s T-Cell Receptor (TCR) technology platform XCEPTOR® which is enabling the fast and efficient discovery, engineering and qualification of a large number of high-affinity and high-specificity TCRs that can be used for Adoptive Cell Therapies i.e. ACTengine® and ACTallo® and TCER® - Bispecifics.

Dominik leads a global-acting Immunology department consisting of four divisions responsible for the TCR discovery platform XCEPTOR®, TCER® - Bispecifics preclinical development, cellular & molecular Immunomonitoring, and Product Science of adoptive cell therapies.

Dominik is an inventor of 10+ patents and patent applications and has co-authored 10+ publications in peer-reviewed journals including Nature, Nature Medicine, Science Immunology, Immunity, Lancet Oncology.

Agenda Sessions

  • Overcoming Challenges in the Generation of Bispecific T Cell-Engaging Receptor (TCER®) Molecules Targeting Tumor Antigens